Eargo, Inc.

NasdaqGS:EAR Rapport sur les actions

Capitalisation boursière : US$53.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo Dividendes et rachats

Dividende contrôle des critères 0/6

Eargo n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

-51.7%

Rendement des rachats

Rendement total pour l'actionnaire-51.7%
Rendement futur des dividendesn/a
Croissance des dividendesn/a
Prochaine date de paiement du dividenden/a
Date ex-dividenden/a
Dividende par actionn/a
Ratio de distributionn/a

Mises à jour récentes sur les dividendes et les rachats

Pas de mise à jour

Recent updates

Seeking Alpha • Aug 30

Eargo: Straining To Be Heard

Summary Today, we take our first look at a small medical device company called Eargo, Inc. whose stock has slumped 90% over the past year. A good portion of the decline was caused by two key issues, both of which company management is hoping to put in the rearview mirror. An investment analysis follows in the paragraphs below. The art of conversation is the art of hearing as well as of being heard."― William Hazlitt Today, we put Eargo, Inc.(EAR) in the spotlight for the first time. This company has a variety of issues recently that have caused the stock to nosedive deep into 'Busted IPO' territory. Are brighter times on the horizon? An analysis follows below. Seeking Alpha Company Overview: Eargo, Inc. is a small medical device maker headquartered in San Jose, CA. The company markets and sells hearing aids through direct-to-consumer and through omni-channels. The stock currently has an approximate market capitalization of $75 million. The company launched the latest version of its hearing aid line, the Eargo 6 in January of this year. The Eargo 6 is an FDA Class II exempt hearing device featuring Sound Adjust technology that automatically optimizes the soundscape as the user moves between environments. June Company Presentation The company has been dogged by two major issues since it went public. The first was a criminal investigation initiated by the U.S. Department of Justice related to insurance reimbursement claims submitted by the company on behalf of its customers covered by the Federal Employee Health Benefits (FEHB) program. Management denied wrongdoing but settled this issue for $34.4 million in the Spring of this year. June Company Presentation Eargo also no longer accepted insurance as a method of direct payment in late 2021. In the second quarter of this year, Eargo operated on a cash-pay only basis which tanked sales (see section below). The company did get some very good news on this front two weeks ago as the FDA disclosed it would allow the sale of some hearing aids over the counter beginning in October. June Company Presentation The company has shipped over 110,000 hearing aid devices in its history and believes the market is significantly underpenetrated especially for its in-ear devices that offer several advantages to traditional hearing aids. June Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. The company had a GAAP loss of 78 cents a share as revenues plunged nearly 70% on a year-over-year basis to $7.25 million. Both top and bottom lines missed expectations badly. Returns rose to a third of sales from just less than a quarter in the same period a year ago. GAAP gross margin was 34.7%, compared to 71.8% in 2Q2021. Management stated via its earnings press release, the company would be focused on four key areas going forward. Eargo's omni-channel growth strategy Potentially regaining insurance coverage of Eargo for government employees under the FEHB program Refining and expanding the company's physical retail strategy Optimize the cash-pay business while continuing to invest in innovation. June Company Presentation Analyst Commentary & Balance Sheet: Wells Fargo ($10 price target), JPMorgan ($11 price target) and William Blair either maintained or downgraded Eargo to a Hold in the fourth quarter of 2021, but no analyst firms I can find have issued any ratings on Eargo so far in 2022. Just over one out of every ten shares are currently held short. Two insiders sold just over $40,000 in aggregate earlier this month. Another insider sold less than $15,000 worth of equity in March. That has been the only insider activity in Eargo's shares so far in 2022. The company ended the second quarter of the year with just over $106 million in cash and marketable securities on its balance sheet. This is almost entirely due to an issuance of $100 million senior secured convertible notes that occurred late in June. This is the core tranche of a $125 million strategic investment from Patient Square Capital. $16.2 million of these proceeds were used to pay off a previous debt obligation. Management will seek stockholder approval to increase the number of authorized shares and issue full potential amount of note conversion shares at its annual meeting in October of this year. If approved, this will consist of new shares of common stock created by a rights offering.
Seeking Alpha • Aug 16

Eargo jumps 77% following FDA rule on OTC hearing aids

Microcap Eargo (NASDAQ:EAR) closed up 77% on Tuesday following the U.S. FDA's announcement that it would allow the sale of some hearing aids over the counter beginning in October. Average daily volume for the company is ~4.2M shares. ~31.8M shares traded hands on Tuesday. Seeking Alpha's Quant Rating views Eargo (EAR) as a strong sell.
Seeking Alpha • Aug 08

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo press release (NASDAQ:EAR): Q2 Non-GAAP EPS of -$0.78 misses by $0.55. Revenue of $7.25M (-68.3% Y/Y) misses by $21.05M.
Seeking Alpha • Jul 05

Eargo completes $100M senior secured convertible notes issuance

Medical device company Eargo (NASDAQ:EAR) completed the issuance of $100M senior secured convertible notes to Patient Square Capital on Jun. 28. ~$16.3M of the net proceeds was used to repay all existing third-party indebtedness and related pay-off expenses. The remaining proceeds are intended to be used for working capital purposes and to fund general business requirements. Source: Press Release
Seeking Alpha • Dec 30

Eargo: A Binary Play On Hearing Loss

Eargo has exhibited stupendous sales growth in recent years and that looks set to continue. But this growth comes at the cost of significant cash outflows that have largely increased over time. The company's value is implied to be very small at this time, which could lead to significant upside if things go right. But significant risks definitely exist, making the company a binary prospect currently.
Seeking Alpha • Oct 08

Eargo Is A High Risk 'Option' With High Potential

Eargo Inc. is a US-based small-cap public company that manufactures and distributes Completely-In-Canal (CIC) hearing aids throughout the country. The company will be one of the beneficiaries of promoting sales of OTC hearing aids in the United States. Eargo Inc. has created a highly competitive product that meets high-quality standards at an affordable price.
Article d’analyse • Jul 10

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

In this article we are going to estimate the intrinsic value of Eargo, Inc. ( NASDAQ:EAR ) by estimating the company's...
Article d’analyse • Jan 16

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

If you want to know who really controls Eargo, Inc. ( NASDAQ:EAR ), then you'll have to look at the makeup of its share...

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de EAR ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de EAR ont augmenté.

Rendement des dividendes par rapport au marché

Eargo Rendement des dividendes par rapport au marché
Comment le rendement du dividende de EAR se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (EAR)n/a
25% du marché (US)1.4%
25% du marché (US)4.2%
Moyenne du secteur (Medical Equipment)2.1%
Analyste prévisionnel (EAR) (jusqu'à 3 ans)n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de EAR par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de EAR par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de EAR afin de déterminer si les dividendes versés sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car EAR n'a signalé aucun versement.

Découvrir des entreprises qui versent des dividendes élevés

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/02/20 20:45
Cours de l'action en fin de journée2024/02/20 00:00
Les revenus2023/09/30
Revenus annuels2022/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Eargo, Inc. est couverte par 4 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Robert HopkinsBofA Global Research
Robert MarcusJ.P. Morgan
Lawrence BiegelsenWells Fargo Securities, LLC